CIP systems in the pharmaceutical industry

A CIP (Cleaning In Place) system is an automated, validated cleaning system for pharmaceutical process installations. It is used for cleaning product contact parts such as tanks, pipes, filters and heat exchangers without disassembly, with fully controlled and documented process parameters.

CIP is essential due to: Strict GMP and compliance requirements Prevention of cross–contamination Control of active substances (APIs) Reproducibility and traceability Mandatory validation and documentation Insufficient cleaning can have a direct impact on patient safety.

The most important critical parameters are:

• Time (contact and cycle time)
• Temperature
• Chemical concentration
• Flow and turbulence
• Conductivity and pH

These parameters must be monitored, logged and secured.

CIP validation typically consists of:

• Risk analysis and worst–case approach
• Establishing acceptance criteria
• IQ, OQ and PQ
• Chemical residue analysis
• Microbiological and endotoxin testing

Validation must comply with GMP guidelines and be audit proof.

Prevention is done by:

• Product– and API–specific CIP recipes
• Worst–case validation
• Dedicated or separate circuits
• Full documentation and traceability
• Correct order of product batches

This is particularly critical for highly potent substances.

Automation is essential for:

• Reproducible cleaning
• Reduction of human error
• Full logging of process data

Systems must comply with data integrity requirements such as ALCOA+ and 21 CFR Part 11.

Common material choices are:

• Stainless steel 316L with low roughness (e.g. Ra ≤ 0.5 μm or lower)
• Electropolished surfaces (optional)
• FDA and USP Class VI certified seals
• Hygienic connections without dead spaces

Material choice influences cleanability and validation.

Effectiveness is monitored through:

• Rinse water analysis
• TOC measurements
• Specific API residue testing
• Microbiological monitoring
• Visual inspection (where permitted)

All results are recorded according to GMP procedures.

Common configurations include:

• Dedicated CIP systems per installation
• Mobile CIP systems
• Central CIP systems with circuit–by–circuit validation
• Recovery systems (limited use due to risks)
• Integration with SIP and UPW/WFI systems

Choice depends on risk analysis and product portfolio.

Water quality is critical and requires:

• PW, UPW or WFI depending on application
• Continuous monitoring of conductivity and TOC
• Periodic microbiological tests
• Correct design of water loops

Water quality is part of the validation.

Common problems include:

• Insufficient worst–case substantiation
• Poor hygienic design
• Missing or incomplete validation
• Non–qualified measuring instruments
• Insufficient data integrity

These often lead to validation problems and audit findings.

Depending on market and application:

• EU–GMP (EudraLex Volume 4)
• FDA cGMP
• 21 CFR Part 11
• GAMP 5
• ISPE guidelines

CIP systems must demonstrably comply with this.

A pharmaceutical CIP system typically requires the following documentation:

• User Requirements Specification (URS)
• Functional Design Specification (FDS)
• Hardware Design Specification (HDS, indien van toepassing)
• Software Design Specification (SDS)
• Factory Acceptance Test (FAT)
• Site Acceptance Test (SAT)
• Installation Qualification (IQ)
• Operational Qualification (OQ)
• Performance Qualification (PQ)
• Cleaning Validation Protocol & Report

These documents together form the validation file.

The URS describes what the CIP system should do from a user, quality, and compliance perspective, including:

• Cleaning purpose and area of application
• GMP and data integrity requirements
• Critical procesparameters
• The alarm a logging
• Integration with SIP, PW/WFI and SCADA

The URS forms the basis for design and validation.

• FDS: functional description of the system, such as CIP recipes, sequences, interlocks, and alarms
• SDS: Technical description of PLC, HMI and SCADA software

Both documents must be traceable to the URS.

FAT (Factory Acceptance Test):

• Functional operation of the CIP system
• Control of software, alarms and recipes
• Pre-Verification Before Delivery

SAT (Site Acceptance Test):

• Correct installation on site
• Integration with utilities and process equipment
• Basic functional tests in situ

Deviations are recorded and followed up.

The IQ confirms that the CIP system has been installed correctly according to design and specifications:

• Verification of components and materials
• Instrumentation calibration status check
• Verification of P&IDs and electrical schematics
• Software versions and backups

All findings are documented.

During the OQ , it is demonstrated that the system functions within defined limits:

1. Testing CIP recipes
2. Alarm and interlock testing
3. Worst-case parameters (time, temperature, flow)
4. Data logging and Part 11 functionality

OQ focuses on critical process parameters.

The PQ shows that the CIP system consistently cleans effectively under normal production conditions:

• Multiple successful CIP cycles
• Cleaning of worst-case products/APIs
• Residual van analysis, TOC in microbiology
• Acceptance according to predetermined criteria

PQ forms the basis for routine use.

Cleaning validation is the demonstration that:

• Product and detergent residues remain below set limits
• No microbiological or endotoxin contamination occurs
• The process is reproducible and robust

This is recorded in a Cleaning Validation Protocol and Report.

Acceptance criteria are based on:

• Toxicological evaluations (e.g., PDE or MACO)
• GMP guidelines
• Internal quality standards
• Worst-case approaches

These criteria must be approved in advance by QA.

Traceability is achieved through:

• Traceability Matrix (URS → FDS/SDS → IQ/OQ/PQ)
• Version control and change control
• GAMP 5 Rating
• Full audit trail

This is essential for inspections and audits.

Any modification to the CIP system, such as:

• Recipe adjustments
• Software-updates
• Hardware changes must be done through a formal change control process, including risk analysis and requalification if necessary.

Revalidation is required:

• Periodic (according to SOP)
• After significant changes
• With new products or APIs
• Following deviations or trends

The frequency is based on the risk.

Commonly used guidelines are:

• EU-GMP Annex 15
• FDA Guidance on Cleaning Validation
• ISPE Baseline Guides
• FEAT 5

These determine the structure and depth of validation.

Yes, partly:

• Standaard templates voor URS, IQ/OQ/PQ
• Modular validation concept
• Risk-based approach

Full standardization is limited by product-specific risks.